Want the full evidence writeup?
The Stack Protocol builds four complete goal stacks — Energy, Focus, Sleep, Longevity — with exact doses, timing, budget tiers, and a 30-day rollout plan, graded with the same evidence framework behind this page.
EPA vs DHA: Molecular Biology of Two Different Fatty Acids
EPA: Competitive Eicosanoid Displacement and COX/LOX Substrate Competition
EPA's primary anti-inflammatory mechanism operates at the level of enzyme substrate competition. The central inflammatory omega-6 fatty acid — arachidonic acid (AA, 20:4 n-6) — is released from membrane phospholipids by phospholipase A2 (PLA2) during inflammatory signaling. Free AA is then acted on by:
- COX-1/COX-2 (cyclooxygenase): Converting AA → prostaglandin G2 → prostaglandin H2 → 2-series prostaglandins (PGE2, PGI2) and thromboxanes (TXA2) — potently pro-inflammatory, pro-thrombotic, vasoconstrictive
- 5-LOX (5-lipoxygenase): Converting AA → 5-HPETE → leukotriene A4 → leukotriene B4 (LTB4, potent neutrophil chemoattractant) and cysteinyl leukotrienes (LTC4, LTD4, LTE4 — bronchoconstrictors)
When EPA is incorporated into membrane phospholipids (replacing AA), PLA2 releases EPA instead of AA. EPA competes with AA at both COX and 5-LOX as an alternative substrate:
- EPA + COX → 3-series prostaglandins (PGE3, PGI3) and thromboxanes (TXA3) — 10–100× less potent than AA-derived 2-series; TXA3 is essentially inactive vs TXA2
- EPA + 5-LOX → 5-series leukotrienes (LTB5) — 10–30× less potent as a neutrophil chemoattractant than LTB4
The net result: a high EPA:AA membrane ratio produces a fundamentally less inflammatory eicosanoid environment — not by blocking COX/LOX (like NSAIDs/aspirin) but by shifting the substrate pool toward less potent analogues. This is why EPA is described as "anti-inflammatory" without being immunosuppressive — baseline immune function is preserved, but the inflammatory amplitude is attenuated.
Specialized Pro-Resolving Mediators (SPMs): EPA and DHA as Inflammation Resolution Substrates
The most clinically significant advance in omega-3 biology in the last two decades is the discovery of specialized pro-resolving mediators (SPMs) — Charles Serhan's work (Harvard Medical School) identified an entirely new class of lipid mediators derived from EPA and DHA that do not merely reduce inflammation initiation but actively promote its resolution:
- E-series resolvins (RvE1, RvE2, RvE3): Derived from EPA via aspirin-modified COX-2 (or via cytochrome P450) + 5-LOX; RvE1 reduces neutrophil infiltration (50–1000× more potent than EPA alone for this endpoint), promotes macrophage phagocytosis of apoptotic cells (efferocytosis), and reduces TNF-α and IL-12 production
- D-series resolvins (RvD1–RvD6): Derived from DHA via 15-LOX + 5-LOX; RvD1 is a potent activator of macrophage efferocytosis and reduces prostaglandin E2 biosynthesis via COX-2 downregulation
- Protectins/Neuroprotectins (PD1/NPD1): Derived from DHA via 15-LOX; NPD1 (neuroprotectin D1) is produced in the brain by DHA and protects neurons from oxidative stress and apoptosis; reduced in Alzheimer's disease brain tissue vs age-matched controls
- Maresins (MaR1, MaR2): Derived from DHA via macrophage 12-LOX; MaR1 accelerates wound healing, reduces pain sensitization (anti-nociceptive), and promotes gut epithelial regeneration
| Trial | Omega-3 Form | Dose | Population | Primary Outcome | Result |
|---|---|---|---|---|---|
| REDUCE-IT (Bhatt 2018, NEJM) | Pure icosapentaenoic acid (EPA only, Vascepa) ethyl ester | 4g/day (2g BID) | Statin-treated adults, TG ≥150, established CVD or DM + risk factors; n=8,179 | 5-point MACE (CV death, MI, stroke, revascularization, UA hospitalization) | HR 0.75, −25% MACE (P<0.001); significant across all components; benefit seen in both primary and secondary prevention subgroups |
| STRENGTH (Nicholls 2020, JAMA) | EPA+DHA carboxylic acid form (Epanova) — high bioavailability free fatty acid | 4g/day (EPA ~2.2g + DHA ~1.8g) | Similar to REDUCE-IT (statin-treated, elevated TG); n=13,078 | 5-point MACE | HR 0.99 — essentially no benefit; trial stopped early for futility; corn oil placebo raised omega-6 levels, potentially harming control group; DHA may raise LDL-C, partially offsetting EPA anti-inflammatory benefit |
| VITAL (Manson 2019, NEJM) | EPA+DHA mixed (Omacor/Lovaza formulation) ethyl ester | 1g/day | US adults ≥50 (women) or ≥55 (men) without CVD or cancer; n=25,871 | Major CV events + invasive cancer | Primary: NS for overall MACE; significant −28% MI reduction; cancer mortality trend NS; fish consumers (≥1.5 servings/week) showed smaller benefit — floor effect in adequate baseline omega-3 status |
| ASCEND (Bowman 2018, NEJM) | EPA+DHA 1g/day in T2DM | 1g/day | Adults with T2DM, no established CVD; n=15,480 | Serious vascular events (non-fatal MI, non-fatal stroke, TIA, CV death) | HR 0.86 (P=0.045) — borderline significant 14% reduction; first primary prevention signal in T2DM; AR reduction 1.1 percentage points over 7.4 years |
Omega-3 Supplementation Protocol: EPA, DHA, and Goals
- Goal-specific EPA:DHA ratios matter: For cardiovascular risk reduction at the level of REDUCE-IT (highest evidence for secondary prevention): pure EPA (icosapentaenoic acid) 4g/day — requires a prescription in the US (Vascepa); for general cardiovascular primary prevention and triglyceride reduction: EPA+DHA 2–4g/day from high-quality concentrated fish oil; for brain health, mood, and neurological indications: DHA-enriched formulations (DHA:EPA ≥2:1) are preferred because DHA is the structural fatty acid in neural tissue; for anti-inflammatory applications (autoimmune conditions, chronic pain, exercise recovery): EPA-enriched (EPA:DHA ≥2:1) is preferable for the eicosanoid competition and resolvin E-series mechanism; for pregnancy and lactation: DHA 200–600mg/day minimum for fetal neurodevelopment, with the EFSA recommending 200mg DHA above baseline adult DHA intake.
- Bioavailability: take fish oil with your fattiest meal: Ethyl ester omega-3s (most prescription and many OTC fish oils) require pancreatic lipase activity and adequate micellar formation — both of which depend on dietary fat in the same meal. A high-fat breakfast (eggs, avocado) with fish oil can increase EPA+DHA absorption by 60–70% vs taking the same supplement fasted or with a low-fat meal. Re-esterified triglyceride (rTG) forms are less meal-dependent but still benefit from co-administration with fat. Krill oil (phospholipid form) is the exception — bioavailable with or without food because phospholipids are water-dispersible without bile acid micelles.
- Oxidation testing — the most neglected quality factor: Fish oil is highly susceptible to peroxidation because DHA and EPA have 6 and 5 double bonds respectively — each double bond is a potential oxidation site. Oxidized fish oil produces malondialdehyde (MDA), 4-hydroxynonenal (4-HNE), and other lipid peroxidation products that are themselves pro-inflammatory and may negate the anti-inflammatory benefit. A 2015 study (IFFO/Friends of the Sea audit) found ~50% of retail fish oils in New Zealand exceeded international freshness standards for oxidation. Quality indicators: TOTOX value (total oxidation) <26 mEqO₂/kg; peroxide value <5 mEqO₂/kg; anisidine value <20. Reputable brands publish these values on their CoA. Refrigerate fish oil after opening; discard if it smells distinctly fishy or rancid (fresh, high-quality fish oil smells mildly oceanic, not sharp or offensive).
- The ALA dead-end — why flaxseed and chia are not omega-3 substitutes: ALA (18:3 n-3) in plant foods (flaxseed 23g/100g, chia 17g/100g, walnuts 9g/100g) requires the Δ6-desaturase enzyme to begin the conversion chain toward EPA and DHA. This enzyme is rate-limited, easily saturated, and strongly competed by dietary LA (linoleic acid, the dominant omega-6 in most Western diets). A diet high in LA (vegetable oils — sunflower, corn, soybean) dramatically reduces ALA-to-EPA conversion because LA occupies the Δ6-desaturase active site preferentially. Even at maximum ALA intake from a vegetarian diet with no competing LA, EPA conversion reaches only ~10% and DHA conversion essentially zero. Vegans and vegetarians should supplement with algal DHA+EPA (400–600mg DHA + 200–300mg EPA from Schizochytrium, Nannochloropsis, or Crypthecodinium microalgae) — these are the same microalgae that fish eat to produce their EPA/DHA content; algal supplements bypass the fish entirely.
- Bleeding risk — mostly theoretical at supplemental doses: High-dose omega-3 fatty acids (≥3g EPA+DHA/day) reduce platelet aggregation via reduced TXA2 production (EPA displacing AA from platelet COX-1). This theoretically increases bleeding risk, which drove physician caution for decades. However: REDUCE-IT at 4g/day EPA showed no significant increase in serious bleeding events vs placebo. Multiple meta-analyses confirm no clinically significant bleeding increase at ≤4g/day EPA+DHA, even in patients on aspirin or warfarin. The theoretical concern is not supported by RCT evidence. Fish oil's anti-platelet effect is modest compared to aspirin (irreversible COX-1 inhibition) or P2Y12 inhibitors — it should not replace anticoagulant medications and does not require dose adjustment in patients on standard anticoagulation at doses ≤4g/day.
High-Quality Omega-3 Supplements
View High-Potency Omega-3 Fish Oil on Amazon →
Quality checklist for omega-3 supplements: (1) IFOS (International Fish Oil Standards) 5-star certified — this independently verifies purity (heavy metals, PCBs, dioxins below detection) and freshness (TOTOX <26). (2) Form: concentrated fish oil in triglyceride form (rTG preferred) for best absorption; or phospholipid krill oil for convenience without meal requirement. (3) Dose: total EPA+DHA per serving should be stated clearly — "1g fish oil" does not equal "1g EPA+DHA"; typical fish oil is 30% EPA+DHA, so "1g fish oil" = ~300mg EPA+DHA; look for products that clearly state EPA + DHA amounts on the label. (4) Storage: dark glass or opaque HDPE bottles, refrigerate after opening. Softgels should be clear with no brown discoloration when cut open.